# A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

> **NCT02318277** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 176 (actual)

## Conditions studied

- Solid Tumors
- Head and Neck Cancer
- Lung Cancer
- UC (Urothelial Cancer)

## Interventions

- **DRUG:** MEDI4736
- **DRUG:** INCB024360

## Key facts

- **NCT ID:** NCT02318277
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-05
- **Primary completion:** 2019-08-28
- **Final completion:** 2020-10-16
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2022-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02318277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02318277, "A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02318277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*